Incidence of pressure ulcers · individuals at risk of pressure ulcer development
Fatty acid showed no clear difference in pressure ulcer incidence: fatty acid vs olive oil compared with other topical intervention or standard care (low certainty).
2 findings from 1 review
Proportion of participants developing a new pressure ulcer · individuals at risk of pressure ulcer development
Fatty acid may leads to lower pressure ulcer incidence: fatty acid vs control compound compared with other topical intervention or standard care (low certainty).
2 findings from 1 review
Adverse event: fatty acid vs olive oil · individuals at risk of pressure ulcer development
Fatty acid showed no clear difference in adverse event: fatty acid vs olive oil compared with other topical intervention or standard care (low certainty).
1 finding from 1 review
Biochemical markers of essential fatty acid status: EPA and DHA % content of neutrophil membrane · adults and children with cystic fibrosis
1 finding from 1 review
Efficacy (functional outcome) · stroke and/or TIA
It is very uncertain whether marine‐derived n‐3 fatty acids therapy changes primary outcome: efficacy (functional outcome) compared with no marine‐derived n‐3 fatty acids therapy (very low certainty).
2 findings from 1 review
Recurrent events (both ischaemic and haemorrhagic stroke) · stroke and/or TIA
Marine‐derived n‐3 fatty acids therapy showed no clear difference in recurrent events (both ischaemic and haemorrhagic stroke) compared with no marine‐derived n‐3 fatty acids therapy (low certainty).
1 finding from 1 review
Incidence of other type of stroke ‒ not measured · stroke and/or TIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · stroke and/or TIA
Marine‐derived n‐3 fatty acids therapy showed no clear difference in adverse events compared with no marine‐derived n‐3 fatty acids therapy (low certainty).
2 findings from 1 review
Quality of life ‐ not measured · stroke and/or TIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mood · stroke and/or TIA
2 findings from 1 review
Deaths due to vascular events · stroke and/or TIA
2 findings from 1 review
Recurrent events: fatal or non‐fatal (same type of stroke, i.e. ischaemic or haemorrhagic) · stroke and/or TIA
It is very uncertain whether marine‐derived n‐3 fatty acids therapy changes recurrent events: fatal or non‐fatal (same type of stroke, i.e.… compared with no marine‐derived n‐3 fatty acids therapy (very low certainty).
1 finding from 1 review
Incidence of other type of stroke (ischaemic or haemorrhagic): fatal or non‐fatal · stroke and/or TIA
1 finding from 1 review
Health‐related quality of life · stroke and/or TIA
1 finding from 1 review
Relapse · people with multiple sclerosis
It is very uncertain whether polyunsaturated fatty acid (PUFA) changes relapse(assessed as number of participants experiencing relapse) compared with monounsaturated fatty acid (MUFA) (very low certainty).
1 finding from 1 review
Change in validated disability scale ( · people with multiple sclerosis
1 finding from 1 review
Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis
Polyunsaturated fatty acid (PUFA) showed no clear difference in global impression of deterioration (investigator defined global… compared with monounsaturated fatty acid (MUFA) (low certainty).
1 finding from 1 review
MRI activity ‐ not measured · people with multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · people with multiple sclerosis
1 finding from 1 review
Loss of patency by 12 months · Dialysis vascular access outcomes in AVF patients with ESKD
Omega‐3 fatty acids showed no clear difference in loss of patency: compared with placebo (moderate certainty).
1 finding from 1 review